STAT+: The China question is tearing biotech apart

The American biotech industry is divided over partnering with Chinese firms, despite spending $60 billion on Chinese molecules in the first three months of 2026. This investment is expected to double last year's total and has sparked hope for patients awaiting new medicines. However, it has also created tension among industry executives and investors.